REFERENCES:


Disclosure of Interests: None declared, Marco Forinaro: None declared, Giovanni Lapadula: None declared, Fabio Cacciapaglia: None declared, Sergio Colella: None declared, Maria Grazia Anelli: None declared, Giovanni Lapadula: None declared, Marco Fornaro: None declared, Anna Abbruzze: None declared, Tatiana Nevskaya: None declared, Janet Pope Consultant for: Eli Lilly and Company.


SHORT-TERM INFLAMMATORY AND LIPIDS CHANGES IN RHEUMATOID ARTHRITIS PATIENTS INFLUENCE CARDIOVASCULAR RISK ALGORITHMS: A MONOCENTRIC RETROSPECTIVE STUDY

vincenzo venierito, Marco Forinaro, Giuseppe Lopaco, Anna Abbruzze, Sergio Colella, Maria Grazia Anelli, Giovanni Lapadula, Florenzo Iannone, Fabio Cacciapaglia, Policlínico of Bari, Rheumatology Unit, Department of Emergency and Organ Transplantations, Bari, Italy

Background: Chronic inflammation may change lipid profile, thus current EULAR recommendations for cardiovascular (CV) management in polyarthritis suggest to assess cholesterol status when disease activity is stable or in remission. To date it is still unclear whether inflammation mediated changes in lipid profile could influence CV risk algorithms and what score should be considered the reference one for any disease activity status.

Objectives: The aim of this study was to evaluate the influence of lipid profile, disease activity and inflammation modifications on four CV risk algorithms during Treat to Target strategy with biologic agents.

Methods: In this monocentric study we retrospectively evaluated all data recorded from Rheumatoid Arthritis (RA) patients with moderate/high CDAI disease activity, who had started for the first time and maintained a bDMARD agent for at least 6 months, in our Outpatient Clinic from the 1st January 2010 to 31st December 2017. Patients with a prior CV event have been excluded from the analysis. For each patient, we assessed the CV risk in a short time period (within 6 months) to estimate the specific weight of lipids and disease activity related variables, using the Italian CV “Progetto Cuore” score, the QRISK3-2018 score, the Reynolds Risk Score (RRS) and the Expanded Risk Score in RA (ERS-RA). The results of the “Progetto CUORE” and RRS algorithms were multiplied by 1.5, in accordance to the EULAR recommendations for algorithms that do not include specifically RA among variables. Wilcoxon signed-rank test was used to compare CV risk scores during follow-up.

Results: One-hundred thirteen RA patients (female n. 86 (76.8%), mean age (SD) 52.8 (12.9) years, median disease duration (IQR) 26 (13-72) months) were eligible for the analysis. CDAI and C-reactive protein levels decreased significantly either at 3 and 6 months follow-up (p<0.001). At 3 months, we observed a statistically significant increase in mean total cholesterol (TC) from 197.3±38.2 mg/dl to 205.8±37.3 mg/dl (p<0.01), which returned close to baseline levels at 6 months (201.1±34.5 mg/dl - p=0.22 vs baseline). High density lipoprotein (HDL), TC/HDL ratio and triglycerides changes did not reach the statistically significance. The estimated CV risk assessed by the “Progetto Cuore” and QRisk3-2018 did not change during the 6 months’ follow-up. RRS showed a decrease either at 3 and 6 months (p<0.04). Similarly, ESR-RA highlighted a decrease of CV risk either at 3 and 6 months (p<0.01) (see Table I).

Conclusion: All evaluated “Scores” are not influenced by short term lipid changes observed during bDMARDs treatment, being applicable at any status of disease activity. Interestingly, the RRS and ESR-RA scores, evaluating RA inflammatory items, are susceptible to disease activity changes. These results should be taken into account by rheumatologists choosing a CV risk algorithm in daily clinical practice.

<table>
<thead>
<tr>
<th>Score</th>
<th>Baseline</th>
<th>3-month followup</th>
<th>6-month followup</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDAI</td>
<td>518±150</td>
<td>610±120</td>
<td>410±120</td>
</tr>
<tr>
<td>TC (mg/dl)</td>
<td>207±20</td>
<td>208±20</td>
<td>201±20</td>
</tr>
<tr>
<td>HDL (mg/dl)</td>
<td>60±8</td>
<td>65±10</td>
<td>61±10</td>
</tr>
<tr>
<td>RRS</td>
<td>0.41±0.14</td>
<td>0.40±0.14</td>
<td>0.40±0.14</td>
</tr>
<tr>
<td>ESR-RA</td>
<td>0.18±0.38</td>
<td>0.18±0.38</td>
<td>0.18±0.38</td>
</tr>
</tbody>
</table>

Values expressed in median (IQR). SD: standard deviation, CDAI: Composite Disease Activity Index, TC: total cholesterol, HDL: high-density lipoprotein, ESR-RA: Expanded Risk Score in Rheumatoid Arthritis, RRS: Reynolds Risk Score.

* p<0.01 vs baseline

Disclosure of Interests: vincenzo venierito: None declared, Marco Forinaro: None declared, Giuseppe Lopaco: Sobi, Bms, Anna Abbruzze: None declared, Sergio Colella: None declared, Maria Grazia Anelli: None declared, Giovanni Lapadula: None declared, Marco Fornaro: None declared, Anna Abbruzze: None declared, Tatiana Nevskaya: None declared, Janet Pope Consultant for: Eli Lilly and Company.